Copenhagen, Denmark - 28 May 2026 - Cessatech A/S (“Cessatech” or the “Company”), a late-stage paediatric specialty company developing and commercializing non-invasive hospital medicines for children, today announced the interim report for the three months ended March 31, 2026. ​The report is available on Cessatech’s website.

First quarter financial results 2026 (1 January - 31 March)​

• Net revenue was KDKK 0 ​

• Operating result was KDKK -3.762 ​

• Net result was KDKK -3.228​

• Cash at bank end of the period was KDKK 5.316​

• Earnings per share* was DKK -0,17​

• Solidity** was 87% ​

*Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 31 March 2026 amounted to 18.576.437 shares, the average number of shares during the first quarter was 18.576.437 **Solidity: Total equity divided by total capital and liability. 

The Interim Report has not been reviewed by the Company’s auditor.

Progressing CT001 in US and Europe​
Jes Trygved, CEO at Cessatech said: ​“We continue to make solid progress advancing CT001 towardscommercialisation, although CT001 has not yet entered the U.S.market as initially anticipated. The extended timeline reflects theadditional time required to complete final manufacturingvalidation, stability studies and quality assurance activities prior toproduct release. Together with our partners, we remain focused oncompleting these final steps and advancing CT001 towardspotential availability for paediatric patients in the U.S. and Europe.In addition, we also had the opportunity to join the Annual PainPractice meeting in Denver, US (SPPM), to present Study 0202 fromCT001, which was very well received.”​

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com